Positron emission tomography and colorectal cancer.
Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality. Molecular imaging using positron emission tomography (PET) is now an integral part of multidisciplinary cancer care. In this review, we discuss the role of PET in CRC including well established indications in the assessment of recurrent disease and emerging applications such as initial staging, monitoring therapy efficacy and using PET for radiotherapy planning. With rapid advancement in imaging technology, we also discuss the future potential of combining PET and magnetic resonance imaging and the use of novel radiotracers.
Lin
Michael
M
Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, Australia; University of New South Wales, Sydney, Australia. michael.lin@swsahs.nsw.gov.au
Wong
Karen
K
Ng
Weng Leong
WL
Shon
Ivan Ho
IH
Morgan
Matthew
M
D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000628:therapy; D055088:Early Detection of Cancer / Q000379:methods*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000592:standards* / Q000639:trends; D011379:Prognosis
D019788:Fluorodeoxyglucose F18